Document text
Principal Investigator: Sagar Prasad Yadavali
Organization: INFINIFLUIDICS, INC.
Fiscal Year: 2022
Award: $293,405
Funding agency: National Institute of General Medical Sciences
Abstract
Infini Fluidics is developing a Very Large-Scale Microfluidic Integration (VLSMI) chip for producing lipid
nanoparticles (LNPs) for RNA therapeutics that can be scaled by a dynamic range of 1000x—from 100 mL/hr to
100 L/hr—thus enabling efficient and affordable use across all phases of drug development. LNPs are promising
drug delivery vehicles that have been critical in the clinical translation of RNA therapeutics and vaccines, most
notably the COVID-19 mRNA vaccines produced by Pfizer and Moderna. The COVID-19 pandemic has created
unprecedented demand for rapid production of LNPs on a global scale, and this has highlighted some of the
major limitations of current production methods. Indeed, a key challenge toward the broad clinical translation of
LNP-based RNA therapeutics and vaccines is the development of formulation strategies that can robustly
produce precisely defined formulations while accommodating scalable throughputs ranging from early
development to clinical translation.
To solve this problem, Infini Fluidics is developing the VLSMI chip, enabling scaling of production by 1000-fold
while maintaining the potency typical of LNPs generated using microfluidics, thus enabling efficient and
affordable production of high-quality LNPs across the phases of drug development. Infini’s proposed VLSMI
architecture integrates tens to hundreds of microfluidic mixing units onto a single, 4-inch silicon chip, just like
transistors in a computer chip. The individual mixing units allow unprecedented control of LNP physiochemical
and functional properties, while hundreds of these units allow flexible manufacturing of LNPs for clinical-phase
trials or industrial-scale manufacturing.
The specific aims of this Phase I project are 1: To evaluate the mixing efficiency of staggered herringbone mixing
(SHM) design units at various lengths and flow rates using fluorescent images, Infini will evaluate four different
device designs, implemented in silicon and glass, which is more compatible with the stringent requirements of
pharmaceutical manufacturing. Mixing dynamics will be evaluated to identify the best performing SHM designs
to synthesize LNPs, and 2: To evaluate LNP properties to determine the uniformity of the LNPs by encapsulating
poly(C) as a model nucleic acid; here, Infini will evaluate LNP properties to demonstrate LNP production is
predictable and accurate for commercial scale.
Infini Fluidics’ VLSMI chip solution will enable the fine control over LNP physiochemical and functional properties
that is necessary for high LNP quality and potency and that has so far eluded macroscale LNP production
methods. This technology can be widely applied to accelerate the development, evaluation, and distribution of
RNA-based therapeutics and vaccines, helping to grow this burgeoning and promising field. This will enable
success in new therapeutic areas and allow a timelier response to emerging pathogens.
Terms: <Address><Advanced Development><Architecture><Area><Biologic Products><Biological Agent><Biological Products><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 test><COVID-19 tests><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 test><COVID19 tests><CV-19><CV19><Cancer Treatment><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cell Body><Cells><Clinical><Communicable Diseases><Cyclic GMP><Cytosine Polynucleotides><DNA Therapy><Development><Device Designs><Devices><Disease Outbreaks><Dose><Drug Delivery><Drug Delivery Systems><Effectiveness><Elements><Encapsulated><Engineering / Architecture><Ensure><Evaluation><Formulation><Gene Transfer Clinical><Generalized Growth><Generations><Genetic Intervention><Glass><Growth><Guanosine Cyclic Monophosphate><Heart Vascular><Human><Individual><Industrialization><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Instruction><Length><Liquid substance><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Maps><Methods><Microfluidics><Modeling><Modern Man><Non-Polyadenylated RNA><Nucleic Acids><Outbreaks><Patients><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Phase><Plants><Play><Poly C><Polycytidylic Acids><Problem Solving><Process><Production><Property><Public Health><RNA><RNA Gene Products><RNA based therapeutics><RNA delivery><RNA vaccine><RNA-based vaccine><Ribonucleic Acid><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 test><SARS-CoV-2 tests><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Scientific Advances and Accomplishments><Scientist><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Si element><Silicon><Speed><Sterility><System><Technology><Therapeutic><Time><TimeLine><Tissue Growth><Transistors><Translations><Vaccine Production><Vaccines><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><anticancer therapy><base><biologics><biopharmaceutical><biotherapeutic agent><cGMP><cancer immunotherapy><cancer therapy><cancer-directed therapy><circulatory system><clinical translation><computer chip><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 test><coronavirus disease 2019 tests><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus infectious disease-19><cost><delivery vector><delivery vehicle><design><designing><developmental><drug development><emerging pathogen><flexibility><flexible><fluid><fluorescence imaging><fluorescent imaging><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><homopolymer 5'-Cytidylic acid><immune-based cancer therapies><immunotherapy for cancer><immunotherapy of cancer><improved><interest><lipid based nanoparticle><lipid nanoparticle><liquid><mRNA vaccine><mRNA-based vaccine><microchip><new drug treatments><new drugs><new pathogen><new technology><new therapeutics><new therapy><new vaccines><next generation therapeutics><next generation vaccines><novel drug treatments><novel drugs><novel pathogen><novel technologies><novel therapeutics><novel therapy><novel vaccines><ontogeny><polydimethylsiloxane><portability><produce vaccines><response><scientific accomplishments><scientific advances><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 test><severe acute respiratory syndrome coronavirus 2 tests><sterile><success><therapeutic RNA><µfluidic>